Biosimilars Buyout? AstraZeneca Reportedly Stalking Korea’s Celltrion
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca may be in the running to acquire Korea’s biosimilars frontrunner Celltrion, according to a local media report.